» Articles » PMID: 38933195

Deep Learning Framework for Comprehensive Molecular and Prognostic Stratifications of Triple-negative Breast Cancer

Overview
Journal Fundam Res
Date 2024 Jun 27
PMID 38933195
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype. Molecular stratification and target therapy bring clinical benefit for TNBC patients, but it is difficult to implement comprehensive molecular testing in clinical practice. Here, using our multi-omics TNBC cohort ( = 425), a deep learning-based framework was devised and validated for comprehensive predictions of molecular features, subtypes and prognosis from pathological whole slide images. The framework first incorporated a neural network to decompose the tissue on WSIs, followed by a second one which was trained based on certain tissue types for predicting different targets. Multi-omics molecular features were analyzed including somatic mutations, copy number alterations, germline mutations, biological pathway activities, metabolomics features and immunotherapy biomarkers. It was shown that the molecular features with therapeutic implications can be predicted including the somatic mutation, germline mutation and PD-L1 protein expression (area under the curve [AUC]: 0.78, 0.79 and 0.74 respectively). The molecular subtypes of TNBC can be identified (AUC: 0.84, 0.85, 0.93 and 0.73 for the basal-like immune-suppressed, immunomodulatory, luminal androgen receptor, and mesenchymal-like subtypes respectively) and their distinctive morphological patterns were revealed, which provided novel insights into the heterogeneity of TNBC. A neural network integrating image features and clinical covariates stratified patients into groups with different survival outcomes (log-rank < 0.001). Our prediction framework and neural network models were externally validated on the TNBC cases from TCGA ( = 143) and appeared robust to the changes in patient population. For potential clinical translation, we built a novel online platform, where we modularized and deployed our framework along with the validated models. It can realize real-time one-stop prediction for new cases. In summary, using only pathological WSIs, our proposed framework can enable comprehensive stratifications of TNBC patients and provide valuable information for therapeutic decision-making. It had the potential to be clinically implemented and promote the personalized management of TNBC.

Citing Articles

Instance-level semantic segmentation of nuclei based on multimodal structure encoding.

Guan B, Chu G, Wang Z, Li J, Yi B BMC Bioinformatics. 2025; 26(1):42.

PMID: 39915737 PMC: 11804060. DOI: 10.1186/s12859-025-06066-8.


Big data in breast cancer: Towards precision treatment.

Zhang H, Hussin H, Hoh C, Cheong S, Lee W, Yahaya B Digit Health. 2024; 10:20552076241293695.

PMID: 39502482 PMC: 11536614. DOI: 10.1177/20552076241293695.


ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.

Ge L, Jin X, Ma D, Wang Z, Liu C, Zhou C Cell Res. 2024; 34(1):58-75.

PMID: 38168642 PMC: 10770380. DOI: 10.1038/s41422-023-00909-w.


A Review of AI-Based Radiomics and Computational Pathology Approaches in Triple-Negative Breast Cancer: Current Applications and Perspectives.

Corredor G, Bharadwaj S, Pathak T, Viswanathan V, Toro P, Madabhushi A Clin Breast Cancer. 2023; 23(8):800-812.

PMID: 37380569 PMC: 10733554. DOI: 10.1016/j.clbc.2023.06.004.


Prediction of clinicopathological features, multi-omics events and prognosis based on digital pathology and deep learning in HR/HER2 breast cancer.

Hu J, Lv H, Zhao S, Lin C, Su G, Shao Z J Thorac Dis. 2023; 15(5):2528-2543.

PMID: 37324098 PMC: 10267923. DOI: 10.21037/jtd-23-445.

References
1.
Coudray N, Ocampo P, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D . Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018; 24(10):1559-1567. PMC: 9847512. DOI: 10.1038/s41591-018-0177-5. View

2.
Yoshida H, Kiyuna T . Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology. World J Gastroenterol. 2021; 27(21):2818-2833. PMC: 8173389. DOI: 10.3748/wjg.v27.i21.2818. View

3.
AbdulJabbar K, Raza S, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A . Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med. 2020; 26(7):1054-1062. PMC: 7610840. DOI: 10.1038/s41591-020-0900-x. View

4.
Bauer K, Brown M, Cress R, Parise C, Caggiano V . Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9):1721-8. DOI: 10.1002/cncr.22618. View

5.
Burstein M, Tsimelzon A, Poage G, Covington K, Contreras A, Fuqua S . Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2014; 21(7):1688-98. PMC: 4362882. DOI: 10.1158/1078-0432.CCR-14-0432. View